Two Akero employees seated and talking at a conference room table

Development Pipeline

Our pipeline is anchored by EFX, a potential best-in-class treatment, if approved, for MASH.

Our pipeline consists of our flagship candidate, efruxifermin (EFX), a novel FGF21 analogue designed to treat MASH by harnessing the natural biology of FGF21. Akero continuously assesses the potential for EFX to be developed for patients with other serious metabolic diseases. We also evaluate opportunities to leverage our expertise in MASH and FGF21 to expand our pipeline.

  • PreCli.
  • Ph1
  • Ph2
  • Ph3
  • Program
  • Phase

Efruxifermin (EFX) Efruxifermin (EFX) Pre-cirrhotic (F2-F3) MASH
  • PH3

Efruxifermin (EFX) Efruxifermin (EFX) Compensated cirrhosis (F4) due to MASH
  • PH3

Research Programs - Undisclosed indications Research Programs - Undisclosed indications
  • Pre-C
Close up of multichannel micropipette filling four small blue centrifuge tubes

EFX is a multi-modal investigational drug that holistically confronts MASH.

Learn About Efruxifermin